>
Expanding horizons: NeOnc Technologies’ bold vision
Publication Date: February 19, 2025
Published By: New York Business Journal
Article Link: https://www.bizjournals.com/newyork/news/2025/02/19/expanding-horizons-neonc-technologies-bold-vision.html
NeOnc Executive Team: (l-r) Patrick Walters, Dr. Thomas Chen, Amir F. Heshmatpour, Keithly A. Garnett
The biotechnology industry is influencing advancements in medicine, agriculture, environmental science, and industrial processes. With its potential to transform human health and address critical global challenges, the industry has experienced unprecedented growth over the past decade.
One area of particular focus within the biotech landscape is oncology, where researchers are working to address some of the most complex medical challenges. With approximately 12,000 new cases annually in the United States alone, glioblastoma has a median survival rate of just 15 to 18 months despite advanced medical care. These sobering statistics show why it is extremely important to develop new treatments that are more effectively able to address these problems.
NeOnc Technologies is making major progress when it comes to potentially addressing such unmet medical needs. The company is focused on advanced, patient-centric solutions that the company believes may have the potential to challenge traditional boundaries in medical treatment. At the helm of NeOnc is Dr. Thomas Chen, a renowned brain surgeon whose dual expertise as a practitioner and innovator drives the company’s efforts to tackle some of the most persistent challenges in neuro-oncology.
Chen’s work is grounded in his firsthand experience with patients battling brain cancer, including glioblastoma. Reflecting on the state of treatment options, he explained, “Patients with glioblastoma still live about 15 to 18 months, even when given the best available care. This disease urgently needs new approaches, particularly in overcoming barriers like the blood-brain barrier that limits effective drug delivery.”
The blood-brain barrier, a natural defense mechanism designed to protect the brain from harmful substances, also presents a significant challenge in treating brain cancers. Conventional drug delivery methods, such as oral or intravenous administration, often fail to effectively penetrate this barrier, says Chen. Recognizing this limitation, NeOnc Technologies is developing an innovative nasal delivery system designed to bypass the blood-brain barrier entirely.
The company’s approach focuses on using a nasal nebulizer; patients inhale therapeutic compounds that would travel directly to the brain via the olfactory nerve. “The olfactory nerve is highly effective for delivering substances to the brain,” says Chen. “ Our method is designed to leverage this natural pathway in an effort to deliver treatment directly to the target site.”
The delivery system is designed for ease of use, allowing patients to administer treatments in the comfort of their own homes. The treatment process involves using a nasal nebulizer four times daily, with each session lasting about 20 minutes. This non-invasive method is designed to eliminate the need for inpatient procedures, potentially offering a patient-friendly alternative to traditional treatments. “Comfort and accessibility are integral to our approach,” Chen noted. “Our approach is designed such that patients could maintain their daily routines while receiving advanced care.”
NeOnc Technologies is built on a robust foundation of intellectual property and scientific research. With 135 patents worldwide — 100 of which have been issued — the company’s portfolio reflects its commitment to innovation. All of its assets, including two Phase II and two Phase I projects, have been developed through Chen’s research and his team’s efforts at the University of Southern California (USC).
Chen’s dedication to advancing neuro-oncology extends beyond the laboratory. His commitment to improving patient results has driven NeOnc’s mission to develop solutions that address medical challenges while prioritizing patient well-being. This patient-centered approach resonates throughout the company’s strategy, from its non-invasive delivery systems to its emphasis on accessibility and comfort.
NeOnc Technologies Holdings, Inc. stands at a transformative crossroads as it prepares for a public listing, signaling a bold new chapter in its journey. As Amir Heshmatpour, executive chairman of NeOnc states, “The company has reached a level of maturity where engaging with broader markets aligns perfectly with our trajectory. Our robust IP portfolio, expanding addressable markets, and comprehensive patent protection position us to make a significant impact.”
Dedicated to advancing innovation in the fight against brain cancer and CNS disease, NeOnc Technologies is committed to delivering groundbreaking solutions to one of medicine’s most critical challenges. With a clear vision, a solid foundation, and a steadfast focus on addressing unmet medical needs, the company is poised to drive meaningful progress and potentially transform the landscape of cancer treatment.